Lion Point Capital, LP
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Nov 2026 | $480,595,987 | Pooled investment vehicles (100%) |
| Apr 2025 to Mar 2026 | $410,264,663 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $517,721,393 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $566,097,826 | Pooled investment vehicles (100%) |
| Apr 2023 | $566,097,826 | Pooled investment vehicles (100%) |
| Apr 2022 to Mar 2023 | $905,084,463 | Pooled investment vehicles (100%) |
Schedule 13D/13G stakes
Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.
No stake currently held at or above 5%.
A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 1 exited, below-5% or retired stake
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.7%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
35 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $20,905,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedTrimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | −2,149,926 | 52,928 | $1,670,407 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterSold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| CUE |
Cue Biopharma, Inc.
Healthcare
|
Reduced | 52,928 | $1,670,407 | 7.99% | |
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
Held | 4,450 | $1,489,815 | 7.13% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
Held | 67,500 | $1,314,225 | 6.29% | |
| FENC |
Fennec Pharmaceuticals Inc.
Healthcare
|
Held | 112,434 | $1,208,665 | 5.78% | |
| RPRX |
Royalty Pharma plc
Healthcare
|
Held | 21,400 | $1,199,898 | 5.74% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Held | 80,000 | $1,132,000 | 5.41% | |
| MIST |
Milestone Pharmaceuticals Inc.
Healthcare
|
Held | 820,000 | $1,098,800 | 5.26% | |
| BNTC |
Benitec Biopharma Inc.
Healthcare
|
Held | 62,000 | $829,560 | 3.97% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Held | 36,000 | $786,960 | 3.76% | |
| BHVN |
Biohaven Ltd.
Healthcare
|
Held | 51,700 | $769,296 | 3.68% | |
| GERN |
Geron Corp
Healthcare
|
Held | 578,000 | $739,840 | 3.54% | |
| QURE |
uniQure N.V.
Healthcare
|
Held | 14,700 | $677,082 | 3.24% | |
| ARDX |
Ardelyx, Inc.
Healthcare
|
Held | 128,650 | $656,115 | 3.14% | |
| LNTH |
Lantheus Holdings, Inc.
Healthcare
|
Held | 5,500 | $610,170 | 2.92% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 8,100 | $592,434 | 2.83% | |
| SRPT |
Sarepta Therapeutics, Inc.
Healthcare
|
Held | 28,500 | $512,145 | 2.45% | |
| HUMA |
Humacyte, Inc.
Healthcare
|
Held | 650,000 | $507,000 | 2.43% | |
| KURA |
Kura Oncology, Inc.
Healthcare
|
Held | 46,000 | $504,620 | 2.41% | |
| VTRS |
Viatris Inc
Healthcare
|
Held | 27,700 | $439,876 | 2.10% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Held | 18,000 | $399,780 | 1.91% | |
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
Held | 5,000 | $372,400 | 1.78% | |
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
Held | 9,100 | $369,733 | 1.77% | |
| PCRX |
Pacira BioSciences, Inc.
Healthcare
|
Held | 13,500 | $342,495 | 1.64% | |
| RGNX |
REGENXBIO Inc.
Healthcare
|
Held | 26,600 | $318,668 | 1.52% | |
| RCKT |
Rocket Pharmaceuticals, Inc.
Healthcare
|
Held | 86,000 | $294,120 | 1.41% | |
| JANX |
Janux Therapeutics, Inc.
Healthcare
|
Held | 19,000 | $291,840 | 1.40% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
Held | 10,500 | $283,290 | 1.36% | |
| GHRS |
GH Research PLC
Healthcare
|
Held | 10,200 | $274,176 | 1.31% | |
| MCRB |
Seres Therapeutics, Inc.
Healthcare
|
Held | 31,570 | $249,087 | 1.19% | |
| AZTA |
Azenta, Inc.
Healthcare
|
Held | 9,700 | $247,544 | 1.18% | |
| JSPR |
Jasper Therapeutics, Inc.
Healthcare
|
Held | 465,000 | $195,765 | 0.94% | |
| INVA |
Innoviva, Inc.
Healthcare
|
Held | 8,200 | $186,222 | 0.89% | |
| IPHA |
Innate Pharma SA
Healthcare
|
Held | 81,151 | $149,317 | 0.71% | |
| ARQT |
Arcutis Biotherapeutics, Inc.
Healthcare
|
Held | 5,250 | $137,655 | 0.66% | |
| SPRB |
Spruce Biosciences, Inc.
Healthcare
|
Held | 1,000 | $54,000 | 0.26% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.